Erasca, Inc. ERAS

ERAS Company Overview

Erasca, Inc. is a U.S.-based clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers. The company operates within the biotechnology and oncology therapeutics industries and concentrates primarily on cancers associated with KRAS mutations, one of the most frequently mutated oncogenic drivers in solid tumors. Erasca’s business model is centered on advancing targeted therapies and combination treatment strategies designed to improve outcomes in genetically defined cancer populations.

The company’s primary value drivers are its oncology drug pipeline, intellectual property portfolio, and strategic collaborations. Key programs have included RAS-targeted small molecules and SHP2 inhibitors intended for combination regimens across multiple tumor types. Erasca was founded in 2018 by biotechnology executives and oncology researchers with experience in targeted therapeutics development. Since its founding, the company has expanded through in-licensing agreements, acquisitions of development-stage assets, and strategic partnerships aimed at building a diversified precision oncology portfolio.